Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Direct Biologics LLC currently manages 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 5 actions are spread across 4 distinct art units, indicating a varied technical focus for their pending matters. The prosecution involves 5 distinct examiners, which means that every single pending office action is being handled by a different individual at the USPTO.
NIEBAUER, RONALD T is the busiest examiner for this portfolio, currently overseeing 1 pending office action. This matches the workload of every other examiner involved, as there are 5 distinct examiners for the 5 pending office actions. There is no examiner concentration in this portfolio, requiring a unique approach for each pending matter.
The 4 distinct art units involved show that the company's 5 pending office actions are not concentrated in a single technical group. Practitioners must be prepared to navigate the specific requirements of 4 different art units and the individual styles of 5 different examiners. The lack of overlap among the 5 distinct examiners means that no single examiner's past decisions will necessarily predict the outcome of other pending actions. This distribution across 4 distinct art units highlights the specialized nature of the pending portfolio in the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCCORMICK, CATHERINE LYNN | 1 | 52.3% | +39.8% |
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
| GOLDBERG, JEANINE ANNE | 1 | 45.4% | +40.5% |
| ROGERS, ERIC JASON | 1 | 56.9% | +33.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17427192 | METHODS AND COMPOSITIONS FOR DEVELOPING TARGET SPECIFIC EXOSOME AND GROWTH FACTOR PRODUCTS | GOLDBERG, JEANINE ANNE | 126d overdue |
| 18340765 | ORAL DELIVERY OF THERAPEUTIC MAMMALIAN CELLS | MCCORMICK, CATHERINE LYNN | 54d |
| 17606514 | METHOD FOR THE TREATMENT OF PERIODONTAL DISEASE USING CHARACTERIZED MESENCHYMAL STEM CELL GROWTH FACTORS AND EXOSOMES | KIM, TAEYOON | — |
| 17418342 | METHODS AND COMPOSITIONS FOR TREATING SKIN AND HAIR DISORDERS | ROGERS, ERIC JASON | — |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| 1631 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18340765 | ORAL DELIVERY OF THERAPEUTIC MAMMALIAN CELLS | MCCORMICK, CATHERINE LYNN | 1638 | Other | Non-Final OA | 54d | Pending | Jun 23, 2023 |
| 17606514 | METHOD FOR THE TREATMENT OF PERIODONTAL DISEASE USING CHARACTERIZED MESENCHYMAL STEM CELL GROWTH FACTORS AND EXOSOMES | KIM, TAEYOON | 1631 | §103 | Final Rejection | — | Pending | Oct 26, 2021 |
| 17427192 | METHODS AND COMPOSITIONS FOR DEVELOPING TARGET SPECIFIC EXOSOME AND GROWTH FACTOR PRODUCTS | GOLDBERG, JEANINE ANNE | 1682 | §103§112DP | Non-Final OA | 126d overdue | Pending | Jul 30, 2021 |
| 17418342 | METHODS AND COMPOSITIONS FOR TREATING SKIN AND HAIR DISORDERS | ROGERS, ERIC JASON | 1638 | §102§103§112DP | Non-Final OA | — | Pending | Jun 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDirect Biologics LLC has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Catherine Lynn Mccormick has the most, with 1 of Direct Biologics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
